JP2005538380A - 神経細胞損傷の分析 - Google Patents

神経細胞損傷の分析 Download PDF

Info

Publication number
JP2005538380A
JP2005538380A JP2004536454A JP2004536454A JP2005538380A JP 2005538380 A JP2005538380 A JP 2005538380A JP 2004536454 A JP2004536454 A JP 2004536454A JP 2004536454 A JP2004536454 A JP 2004536454A JP 2005538380 A JP2005538380 A JP 2005538380A
Authority
JP
Japan
Prior art keywords
marker
specimen
agent
spectrin
sbdp120
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004536454A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005538380A5 (https=
Inventor
ヘイズ，ロナルド，エル．
ワン，ケヴィン，ケー．，ダヴリュー．
パイク，ブレイン，アール．
Original Assignee
ユニヴァーシティ オヴ フロリダ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニヴァーシティ オヴ フロリダ filed Critical ユニヴァーシティ オヴ フロリダ
Publication of JP2005538380A publication Critical patent/JP2005538380A/ja
Publication of JP2005538380A5 publication Critical patent/JP2005538380A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2004536454A 2002-09-11 2003-09-11 神経細胞損傷の分析 Pending JP2005538380A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40992002P 2002-09-11 2002-09-11
PCT/US2003/028406 WO2004025298A1 (en) 2002-09-11 2003-09-11 Analyzing nerve cell damage

Publications (2)

Publication Number Publication Date
JP2005538380A true JP2005538380A (ja) 2005-12-15
JP2005538380A5 JP2005538380A5 (https=) 2007-12-13

Family

ID=31994033

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004536454A Pending JP2005538380A (ja) 2002-09-11 2003-09-11 神経細胞損傷の分析

Country Status (6)

Country Link
US (1) US7291710B2 (https=)
EP (3) EP2348317B1 (https=)
JP (1) JP2005538380A (https=)
AU (1) AU2003270509B2 (https=)
CA (1) CA2498614C (https=)
WO (1) WO2004025298A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007532915A (ja) * 2004-04-15 2007-11-15 ユニバーシティ・オブ・フロリダ・リサーチ・ファンデーション・インコーポレーテッド 神経系傷害および他の神経障害についての生物マーカーとしての神経タンパク質
JP2011511301A (ja) * 2008-02-04 2011-04-07 バンヤン・バイオマーカーズ・インコーポレイテッド 脳損傷を診断または治療するための方法
JP2012500388A (ja) * 2008-08-11 2012-01-05 バンヤン・バイオマーカーズ・インコーポレーテッド 神経学的状態のバイオマーカー検出方法およびアッセイ
JP2013524220A (ja) * 2010-04-01 2013-06-17 バンヤン・バイオマーカーズ・インコーポレイテッド 神経毒性を検出するためのマーカーおよびアッセイ
JP2015172587A (ja) * 2009-06-19 2015-10-01 バンヤン・バイオマーカーズ・インコーポレーテッド 神経学的状態のバイオマーカーアッセイ
US10646555B2 (en) 2010-01-26 2020-05-12 Bioregency, Inc. Compositions and methods relating to argininosuccinate synthetase
US12601749B2 (en) 2008-08-11 2026-04-14 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
CA2578680C (en) * 2004-04-15 2011-06-14 University Of Florida Research Foundation, Inc. Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining
JP5202296B2 (ja) * 2005-04-01 2013-06-05 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド 肝臓傷害のバイオマーカー
US8048638B2 (en) * 2005-04-01 2011-11-01 University Of Florida Research Foundation, Inc. Biomarkers of liver injury
EP1840574A1 (en) 2006-03-30 2007-10-03 Institut Pasteur Use of the alpha chain of brain spectrin and fragments thereof, for diagnosing cerebral diseases
US20140342381A1 (en) * 2008-08-11 2014-11-20 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of neurological condition
WO2011032155A2 (en) 2009-09-14 2011-03-17 Banyan Biomarkers, Inc. Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury
CA2939692C (en) 2013-03-15 2022-10-18 The Trustees Of The University Of Pennsylvania Blood biomarkers that predict persistent cognitive dysfunction after concussion
WO2015066211A1 (en) * 2013-10-29 2015-05-07 Banyan Biomarkers, Inc. Uch-l1 isoforms, assays and devices for detection of a neurological condition
WO2018081649A1 (en) 2016-10-28 2018-05-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05508919A (ja) * 1990-07-26 1993-12-09 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア スペクトリン又はその崩壊生成物の分析による細胞壊死検出
JPH09511332A (ja) * 1994-03-25 1997-11-11 セファロン インク カルパイン活性化を検出する方法およびカルパイン阻害剤を同定する方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116606A (en) * 1989-03-09 1992-05-26 Alt John P Skin treatment method and solution
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
EP0786469B1 (en) 1990-06-11 2006-03-01 Gilead Sciences, Inc. Methods of use of nucleic acid ligands
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05508919A (ja) * 1990-07-26 1993-12-09 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア スペクトリン又はその崩壊生成物の分析による細胞壊死検出
JPH09511332A (ja) * 1994-03-25 1997-11-11 セファロン インク カルパイン活性化を検出する方法およびカルパイン阻害剤を同定する方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6009030209, Ｂｒｉａｎ Ｒ． Ｐｉｋｅ ｅｔ ａｌ．, "Ａｃｃｕｍｕｌａｔｉｏｎ ｏｆ ｎｏｎ−ｅｒｙｔｈｒｏｉｄ αＩＩ−ｓｐｅｃｔｒｉｎ ａｎｄ ｃａｌｐａｉｎ−ｃｌｅａｖｅｄ αＩＩ−ｓｐｅｃｔｒｉｎ ｂｒｅａｋｄｏｗｎ ｐｒｏｄｕｃｔｓ ｉｎ", Ｊｏｕｒｎａｌ ｏｆ Ｎｅｕｒｏｃｈｅｍｉｓｔｒｙ, 2001, Ｖｏｌｕｍｅ ７８ Ｉｓｓｕｅ ６, １２９７−１３０６ *
JPN6009030210, Ａｎｄｒａｓ Ｂｕｋｉ ｅｔ ａｌ．, "Ｃｙｔｏｃｈｒｏｍｅ ｃ Ｒｅｌｅａｓｅ ａｎｄ Ｃａｓｐａｓｅ Ａｃｔｉｖａｔｉｏｎ ｉｎ Ｔｒａｕｍａｔｉｃ Ａｘｏｎａｌ Ｉｎｊｕｒｙ", Ｔｈｅ Ｊｏｕｒｎａｌ ｏｆ Ｎｅｕｒｏｓｃｉｅｎｃｅ, 20000415, ２０（８）, ２８２５−２８３４ *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007532915A (ja) * 2004-04-15 2007-11-15 ユニバーシティ・オブ・フロリダ・リサーチ・ファンデーション・インコーポレーテッド 神経系傷害および他の神経障害についての生物マーカーとしての神経タンパク質
JP2011511301A (ja) * 2008-02-04 2011-04-07 バンヤン・バイオマーカーズ・インコーポレイテッド 脳損傷を診断または治療するための方法
JP2012500388A (ja) * 2008-08-11 2012-01-05 バンヤン・バイオマーカーズ・インコーポレーテッド 神経学的状態のバイオマーカー検出方法およびアッセイ
JP2014199262A (ja) * 2008-08-11 2014-10-23 バンヤン・バイオマーカーズ・インコーポレーテッド 神経学的状態のバイオマーカー検出方法およびアッセイ
US11994522B2 (en) 2008-08-11 2024-05-28 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
US12601749B2 (en) 2008-08-11 2026-04-14 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
JP2015172587A (ja) * 2009-06-19 2015-10-01 バンヤン・バイオマーカーズ・インコーポレーテッド 神経学的状態のバイオマーカーアッセイ
US10646555B2 (en) 2010-01-26 2020-05-12 Bioregency, Inc. Compositions and methods relating to argininosuccinate synthetase
JP2013524220A (ja) * 2010-04-01 2013-06-17 バンヤン・バイオマーカーズ・インコーポレイテッド 神経毒性を検出するためのマーカーおよびアッセイ

Also Published As

Publication number Publication date
EP1546717A1 (en) 2005-06-29
EP2348317A3 (en) 2011-09-07
EP2211176A2 (en) 2010-07-28
AU2003270509A2 (en) 2004-04-30
EP1546717A4 (en) 2007-01-17
US7291710B2 (en) 2007-11-06
US20070003982A1 (en) 2007-01-04
AU2003270509B2 (en) 2009-03-26
AU2003270509A1 (en) 2004-04-30
CA2498614C (en) 2013-04-16
WO2004025298A1 (en) 2004-03-25
EP2348317A2 (en) 2011-07-27
EP2211176A3 (en) 2010-12-08
CA2498614A1 (en) 2004-03-25
EP2348317B1 (en) 2014-12-03

Similar Documents

Publication Publication Date Title
US11994522B2 (en) Biomarker detection process and assay of neurological condition
JP6408041B2 (ja) 神経学的状態のバイオマーカーアッセイ
US7291710B2 (en) Detection of spectrin and spectrin proteolytic cleavage products in assessing nerve cell damage
Rohn et al. Correlation between caspase activation and neurofibrillary tangle formation in Alzheimer’s disease
JP6469760B2 (ja) ニューロン損傷診断のためのマイクロｒｎａ、自己抗体およびタンパク質マーカー
US20120202231A1 (en) Synergistic biomarker assay of neurological condition using s-100b
US20110082203A1 (en) Process to diagnose or treat brain injury
US20140303041A1 (en) In vitro diagnostic devices for nervous system injury and other neural disorders
US20170307640A1 (en) Methods, kits and devices for detecting bii-spectrin, and breakdown products thereof, as biomarkers for the diagnosis of neural injury
JP4933159B2 (ja) アルツハイマー病の診断方法
KR101515211B1 (ko) 간 섬유화 진단용 바이오마커 HtrA2
AU2015203660A1 (en) Process to diagnose or treat brain injury

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100510

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100517

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110218

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110622

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20110826